Please use this identifier to cite or link to this item:
https://ahro.austin.org.au/austinjspui/handle/1/10065
Title: | MDX-060. Medarex. | Austin Authors: | Hu, Xiu Feng;Xing, Pei Xiang | Affiliation: | The Austin Research Institute, Austin Health, Heidelberg 3084, Victoria, Australia | Issue Date: | 1-Dec-2005 | Publication information: | Current Opinion in Investigational Drugs (london, England : 2000); 6(12): 1266-71 | Abstract: | Medarex is developing the antibody MDX-060 for the potential treatment of CD30+ lymphomas, such as Hodgkin's disease and anaplastic large cell lymphomas. Phase I/II clinical trials were underway by December 2002. | Gov't Doc #: | 16370393 | URI: | https://ahro.austin.org.au/austinjspui/handle/1/10065 | Journal: | Current opinion in investigational drugs (London, England : 2000) | URL: | https://pubmed.ncbi.nlm.nih.gov/16370393 | Type: | Journal Article | Subjects: | Animals Antibodies, Monoclonal Antigens, CD30.immunology Antineoplastic Agents.pharmacology.therapeutic use Clinical Trials as Topic Drug Screening Assays, Antitumor Hodgkin Disease.drug therapy.immunology Humans Lymphoma, Large B-Cell, Diffuse.drug therapy.immunology |
Appears in Collections: | Journal articles |
Show full item record
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.